Symptoms Burden and Health-related Quality of Life in Chinese Patients with Primary Biliary Cholangi

来源 :临床与转化肝病杂志(英文版) | 被引量 : 0次 | 上传用户:neusoftlyh
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background and Aims: Primary biliary cholangitis (PBC) is a chronic liver disease that negatively affects the health-related quality of life (HRQoL) of patients. Furthermore, the HRQoL of Chinese patients has been neglected for a long time. The present study aimed to assess the HRQoL of Chi-nese patients with PBC and explore the clinical variables cor-relating to the improvement of itch and fatigue. Methods: This was an observational, cross-sectional study. The PBC-40 and itch numerical rating scales were used to evaluate the symptoms and HRQoL of patients. Results: A total of 383 patients were recruited, and 86.4% were female, with a median age of 55 years (range: 49–63 years). We found that females had significantly higher scores than males in symp-toms (p=0.033) and cognitive domains (p=0.021), and the fatigue domain was higher in elderly patients (p=0.007). Meanwhile, patients whose body mass index was <18.5 had the highest scores in the symptoms (p=0.009), fatigue (p=0.010), and cognitive (p=0.019) domains. Age at par-ticipation (odds ratio [OR]=1.068, p=0.015) and albumin level at 12 months after ursodeoxycholic acid treatment (OR=208.807, p=0.025) were independent factors that af-fected the improvement of the itch and fatigue domains, respectively. Conclusions: The HRQoL of Chinese patients with PBC was significantly impaired depending on sex, age, and body mass index. Age and albumin level were signifi-cantly associated with the improvement of itch and fatigue, respectively. Therefore, treatment and support aimed at these two factors can be provided to improve the HRQoL of patients.
其他文献
目的:探讨1q21扩增(简称1q)对于初治多发性骨髓瘤(NDMM)预后的影响.方法:回顾性分析2014年1月-2020年8月在徐州医科大学附属医院行FISH检测并规范治疗的171例NDMM患者的临床资料,比较伴1q与不伴1q的NDMM患者间的临床特征及生存差异,分析1q对于硼替佐米疗效的影响,探讨NDMM预后的高危因素,研究1q单独存在及与其他高危因素共存对于NDMM预后的影响.结果:①171例NDMM患者中,1q的发生率为45.6%(78/171).与非1q组比较,1q组P53缺失、IgH重排、del(
To the editor,rnWe have read the article titled “Characteristics and Out-come of Exertional Heatstroke Patients Complicated by Acute Hepatic Injury: A Cohort Study” by Ji et al.1 We con-gratulate the authors for this insightful article. In this letter, we
期刊
骨髓增生异常综合征/骨髓增殖性肿瘤(myel-odysplastic/myeloproliferative neoplasms,MDS/MPN)是一组兼具骨髓增生异常综合征(MDS)和骨髓增殖性肿瘤(MPN)特征的罕见的血液系统恶性肿瘤,具有向急性髓系白血病(AML)转化的风险.根据2016年世界卫生组织(WHO)修订的MDS/MPN分类,主要包括以下5个亚型:慢性粒单核细胞白血病(CMML),不典型慢性髓系白血病(aCML),幼年型粒单核细胞白血病(JMML),骨髓增生异常综合征/骨髓增殖性肿瘤伴环形铁
目的:探讨CEBPA基因突变与急性髓系白血病(AML)临床特征及预后的关系.方法:收集2018年1月1日-2020年1月1日初次就诊于我院的154例AML患者(排除M3型)的详细信息,其中CEBPA双突变(CEBPAdm)23例,CEBPA单突变(CEBPAsm)8例,CEBPA突变阴性(CEBPA-)123例.对AML患者的临床特征及预后进行回顾性分析,比较3组患者间完全缓解(CR)率、总生存期(OS)和无进展生存时间(PFS).结果:与CEBPA-组比较,CEBPAdm组初诊年龄小(P=0.002),
单克隆B淋巴细胞增多症(monoclonal B-cell lymphocytosis,MBL)是指健康个体外周血存在低水平的单克隆B淋巴细胞.自90年代初MBL在人群中首次发现,距今近30年的时间里,针对MBL的生物学机制的研究已取得了阶段性进展.MBL是一个存在高度异质性的庞大群体,但迄今为止,针对MBL人群的管理尚无明确的国际共识和指南可循.本文就MBL的诊断及分型、流行病学特点、分子遗传学机制及该人群的管理进行综述.
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic disorders. This study aimed to explore the role of metabolic disorders in screen-ing advanced fibrosis in NAFLD patients. Methods: A total of 246 histologically-pro
A panel of experts from 22 countries recently proposed a name change from nonalcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease, or MAFLD.1 Sub-sequently, new criteria for diagnosing MAFLD were provided to help guide clinici
期刊
To the editor,rnThere remains a huge unmet need for treatment of cir-rhotic ascites. In this letter, we propose that the sodium-glucose cotransporter-2 (SGLT2) inhibitor may be a promis-ing complement for current therapy.
期刊
Background and Aims: The immune system plays vital roles in hepatocellular carcinoma (HCC) initiation and pro-gression. The present study aimed to construct an immune-gene related prognostic signature (IRPS) for predicting the prognosis of HCC patients. M
Spontaneous bacterial peritonitis (SBP) is defined as infec-tion in ascites fluid without evidence of an intra-abdominal treatable source.1 Diagnosis is confirmed by presence of ≥250 cells/mm3 polymorphonuclear cells (PMNs).2 Although SBP responds well to
期刊